Vivtex vs Schrödinger

Side-by-side comparison of AI visibility scores, market position, and capabilities

Schrödinger leads in AI visibility (74 vs 52)
Vivtex logo

Vivtex

ChallengerBioTech

Oral Biologics Drug Delivery

Signed $2.1B Novo Nordisk collaboration (Feb 2026). Platform enables oral delivery of proteins and peptides (historically injection-only). MIT Langer lab spinout.

AI VisibilityBeta
Overall Score
C52
Category Rank
#67 of 198
AI Consensus
84%
Trend
stable
Per Platform
ChatGPT
52
Perplexity
51
Gemini
50

About

Vivtex is an MIT Langer Laboratory spinout that has developed a drug delivery platform enabling oral administration of biologics — proteins, peptides, and other large molecules — that have historically required injection because they are degraded by stomach acid and too large to absorb through the intestinal wall. In February 2026, Vivtex signed a $2.1 billion collaboration agreement with Novo Nordisk for the development of oral formulations of biologic drugs in obesity, diabetes, and metabolic disease.

Full profile
Schrödinger logo

Schrödinger

LeaderLife Sciences & BioTech

Computational Drug Discovery

Physics-based molecular simulation platform used by 1,700+ organizations. Q3 2025 software revenue up 54% YoY; $150M Novartis collaboration signed in early 2025.

AI VisibilityBeta
Overall Score
B74
Category Rank
#1 of 198
AI Consensus
84%
Trend
stable
Per Platform
ChatGPT
74
Perplexity
80
Gemini
75

About

Schrödinger was founded in 1990 by Richard Friesner and David Pearlman in New York City, building physics-based computational methods for molecular simulation. For over 30 years the company has developed the industry-leading molecular modeling suite used by academic researchers, biotech startups, and large pharmaceutical companies to predict molecular properties, optimize lead compounds, and design drugs with greater precision than traditional empirical approaches.\n\nSchrödinger's platform—spanning FEP+ (free energy perturbation), Glide docking, WaterMap, and machine learning-enhanced property prediction—is used by over 1,700 organizations across pharma, biotech, and materials science. In early 2025, the company signed a landmark $150 million upfront collaboration with Novartis for multi-target drug discovery with potential milestones exceeding $2.3 billion. Software revenue grew 54% year-over-year in Q3 2025 as pharmaceutical companies accelerated adoption of computational-first drug discovery. Schrödinger also operates a proprietary drug pipeline, with SGR-1505 (MALT1 inhibitor) in Phase 1 for B-cell malignancies.\n\nSchrödinger occupies a unique hybrid position—part software platform, part drug discovery company—and is a benchmark of the AI/physics-based drug discovery movement. The company is publicly traded (SDGR) and is recognized as an essential tool for the modern small-molecule drug discovery workflow.

Full profile

AI Visibility Head-to-Head

52
Overall Score
74
#67
Category Rank
#1
84
AI Consensus
84
stable
Trend
stable
52
ChatGPT
74
51
Perplexity
80
50
Gemini
75
54
Claude
74
47
Grok
78

Key Details

Category
Oral Biologics Drug Delivery
Computational Drug Discovery
Tier
Challenger
Leader
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only Vivtex
Oral Biologics Drug Delivery
Only Schrödinger
Computational Drug Discovery

Integrations

Only Vivtex

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.